<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584727</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0714A</org_study_id>
    <nct_id>NCT00584727</nct_id>
  </id_info>
  <brief_title>In-office Evaluation of Two Toric Soft Contact Lenses and a Spherical Soft Contact Lens</brief_title>
  <official_title>Evaluation of Fit and Visual Acuity of the Cypress Toric Lens in Two Phases: Part A: A Non-Dispensing Comparison to SofLens66® Toric and Acuvue® 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foresight Regulatory Strategies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relative performance of a new toric soft
      contact lens against a toric and a spherical contact lens currently available in market,
      specifically with regards to the fit and visual acuity as well as the comfort, vision and
      satisfaction while in the practitioner's office. Approximately 2 hours duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-dispensing, single-masked (subject-masked), randomised, controlled study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Number of eyes with Distance Visual Acuity 20/20 or better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Vision</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>A weighted combined score calculated from individual confort-vision related questions asked on a 1-5 scale, 1=most negative resonse to 5=most positive response, was used to derive vision scores. The analysis shows the difference in outcome between test and control. &gt;0=greater vision, &lt;0=lesser vision.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Orientation Within 5 Degrees</measure>
    <time_frame>1 minute</time_frame>
    <description>Meaures in what position does the lens sit on the eye at insertion and is measured in degrees of rotation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens Stability Within 5 Degrees</measure>
    <time_frame>1 minute</time_frame>
    <description>Measures if the lens changes position on the eye as it is worn and is measured in degrees of rotation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Comfort.</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale, 1=most negative response to 5=most positive response, was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control. &gt;0=comfortable, &lt;0=uncomfortable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>end of study</time_frame>
    <description>This outcome measures which lens the subjects preferred to wear.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>senofilcon A/alphafilcon A/etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alphafilcon A/etafilcon A/senofilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A/senofilcon A/alphafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon A/etafilcon A/alphafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alphafilcon A/senofilcon A/etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A/alphafilcon A/senofilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A toric contact lens</intervention_name>
    <description>contact lens</description>
    <arm_group_label>senofilcon A/alphafilcon A/etafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/etafilcon A/senofilcon A</arm_group_label>
    <arm_group_label>etafilcon A/senofilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>senofilcon A/etafilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/senofilcon A/etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A/alphafilcon A/senofilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>alphafilcon A toric</intervention_name>
    <description>contact lens</description>
    <arm_group_label>senofilcon A/alphafilcon A/etafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/etafilcon A/senofilcon A</arm_group_label>
    <arm_group_label>etafilcon A/senofilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>senofilcon A/etafilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/senofilcon A/etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A/alphafilcon A/senofilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A sphere</intervention_name>
    <description>contact lens</description>
    <arm_group_label>senofilcon A/alphafilcon A/etafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/etafilcon A/senofilcon A</arm_group_label>
    <arm_group_label>etafilcon A/senofilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>senofilcon A/etafilcon A/alphafilcon A</arm_group_label>
    <arm_group_label>alphafilcon A/senofilcon A/etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A/alphafilcon A/senofilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. be at least 18 and less than or equal to 39 years of age and have a need for vision
             correction in BOTH eyes (monovision or uniocular fitting is NOT allowed).

          2. be of Asian descent (Japanese, Chinese, Korean, Polynesian or other Asian ancestry)
             and have Asian Eye anatomy

          3. have successfully worn toric or spherical soft (hydrogel or silicone hydrogel) contact
             lenses for at least 4-weeks prior to enrollment in the study.

          4. be able and willing to adhere to the instructions set forth in the protocol.

          5. agree to wear their contact lenses in both eyes on a daily wear schedule for at least
             8 hours per day every day during the study.

          6. have a distance spherical component between -1.00 D and -5.50 D with cylinder in the
             range of 0.75 D to 2.25 D and cylinder axis within 10 ° of the vertical and within 20
             ° of the horizontal in both eyes

          7. have a best corrected manifest refraction visual acuity of at least 20/25 or better in
             each eye.

          8. be in good general health, based on his/her knowledge.

          9. read, be given an explanation of, indicate understanding of, and sign the STATEMENT OF
             INFORMED CONSENT.

        Exclusion Criteria:

          1. The subject is a rigid gas permeable (RGP) or daily disposable soft lens wearer.

          2. The presence of clinically significant (grade 3 or 4) anterior segment abnormalities;
             inflammations such as iritis; or any infection of the eye, lids, or associated
             structures.

          3. The presence of ocular or systemic disease or need for medication which might
             interfere with contact lens wear or which would cause the lenses to be removed more
             than twice a day. (i.e., Sjögren's syndrome, type II diabetes, etc).

          4. Slit lamp findings that would contraindicate contact lens wear such as:

               -  Pathological dry eye or associated findings

               -  Pterygium or corneal scars within the visual axis

               -  Neovascularization &gt;1mm in from the limbus

               -  History of giant papillary conjunctivitis (GPC) worse than Grade 2

               -  Anterior uveitis or iritis (past or present)

               -  Seborrhoeic eczema, seborrhoeic conjunctivitis

          5. A history of recurrent erosions, corneal infiltrates, corneal ulcer or fungal
             infections.

          6. A known history of corneal hypoesthesia (reduced corneal sensitivity.)

          7. Aphakia, keratoconus or a highly irregular cornea.

          8. Current pregnancy or lactation (to the best of the subject's knowledge).

          9. Active participation in another clinical study at any time during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Chin, O.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>James Fujimoto, O.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Weslie Hamada, OlD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur T. Kobayashi, O.D., Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Kuwuabara, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Care Associates of Hawaii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Nakano, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mark E. Nakano Optometric Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ikuko Sugimoto, O.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Kevin Rosin, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drs. Farkas, Kassalow, Resnick &amp; Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Kao, O.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>December 5, 2008</results_first_submitted>
  <results_first_submitted_qc>January 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2010</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <name_title>Kurt Moody, OD, FAAO./ Manager, Clinical Research</name_title>
    <organization>Vistakon</organization>
  </responsible_party>
  <keyword>astigmatism</keyword>
  <keyword>visual acuity</keyword>
  <keyword>fit</keyword>
  <keyword>comfort</keyword>
  <keyword>satisfaction</keyword>
  <keyword>contact lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon A/Alphafilcon A/Etafilcon A</title>
          <description>First Intervention: senofilcon A toric contact lenses Second Intervention: alphafilcon A toric contact lenses Third Intervention: etafilcon A sphere contact lenses</description>
        </group>
        <group group_id="P2">
          <title>Alphafilcon A/Etafilcon A/Senofilcon A</title>
          <description>First Intervention: alphafilcon A toric contact lenses Second Intervention: etafilcon A sphere contact lenses Third Intervention: senofilcon A toric contact lenses</description>
        </group>
        <group group_id="P3">
          <title>Etafilcon A/Senofilcon A/Alphafilcon A</title>
          <description>First Intervention: etafilcon A sphere contact lenses Second Intervention: senofilcon A toric contact lenses Third Intervention: alphafilcon A toric contact lenses</description>
        </group>
        <group group_id="P4">
          <title>Senofilcon A/Etafilcon A/Alphafilcon A</title>
          <description>First Intervention: senofilcon A toric contact lenses Second Intervention: etafilcon A sphere contact lenses Third Intervention: alphafilcon A toric contact lenses</description>
        </group>
        <group group_id="P5">
          <title>Alphafilcon A/Senofilcon A/Etafilcon A</title>
          <description>First intervention: alphafilcon A toric Second intervention: senofilcon A toric Third intervention: etafilcon A sphere</description>
        </group>
        <group group_id="P6">
          <title>Etafilcon A/Alphafilcon A/Senofilcon A</title>
          <description>First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Completed Population</title>
          <description>Only participants that completed the study are included (n=88)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Number of eyes with Distance Visual Acuity 20/20 or better</description>
        <time_frame>15-20 minutes</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88 subjects,176 eyes)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
          <group group_id="O3">
            <title>Etafilcon A Sphere</title>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Number of eyes with Distance Visual Acuity 20/20 or better</description>
          <population>Analysis includes participants who completed the study per protocol (n=88 subjects,176 eyes)</population>
          <units>Eyes with Snellen VA 20/20 or better</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis was senofilcon A toric was superior to etafilcon A sphere by having more eyes see 20/20</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Vision</title>
        <description>A weighted combined score calculated from individual confort-vision related questions asked on a 1-5 scale, 1=most negative resonse to 5=most positive response, was used to derive vision scores. The analysis shows the difference in outcome between test and control. &gt;0=greater vision, &lt;0=lesser vision.</description>
        <time_frame>15-20 minutes</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
          <group group_id="O3">
            <title>Etafilcon A Sphere</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Vision</title>
          <description>A weighted combined score calculated from individual confort-vision related questions asked on a 1-5 scale, 1=most negative resonse to 5=most positive response, was used to derive vision scores. The analysis shows the difference in outcome between test and control. &gt;0=greater vision, &lt;0=lesser vision.</description>
          <population>Analysis includes participants who completed the study per protocol (n=88)</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2845" spread="0.098"/>
                    <measurement group_id="O2" value="0.1332" spread="0.098"/>
                    <measurement group_id="O3" value="-0.4310" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis was senofilcon A toric was superior to etafilcon A sphere.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1334</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3625</ci_lower_limit>
            <ci_upper_limit>0.7155</ci_upper_limit>
            <estimate_desc>Mean difference was senofilcon A toric minus etafilcon A sphere.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Orientation Within 5 Degrees</title>
        <description>Meaures in what position does the lens sit on the eye at insertion and is measured in degrees of rotation.</description>
        <time_frame>1 minute</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88 subjects, 176 eyes)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
        </group_list>
        <measure>
          <title>Lens Orientation Within 5 Degrees</title>
          <description>Meaures in what position does the lens sit on the eye at insertion and is measured in degrees of rotation.</description>
          <population>Analysis includes participants who completed the study per protocol (n=88 subjects, 176 eyes)</population>
          <units>degrees</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Aletrnative hypothesis was senofilcon A toric was superior to alphafilcon A toric by having more eyes within 5 degrees.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2161</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lens Stability Within 5 Degrees</title>
        <description>Measures if the lens changes position on the eye as it is worn and is measured in degrees of rotation.</description>
        <time_frame>1 minute</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88 subjects, 176 eyes)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
        </group_list>
        <measure>
          <title>Lens Stability Within 5 Degrees</title>
          <description>Measures if the lens changes position on the eye as it is worn and is measured in degrees of rotation.</description>
          <population>Analysis includes participants who completed the study per protocol (n=88 subjects, 176 eyes)</population>
          <units>degrees</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis was senofilcon A toric was superior to alphafilcon A toric by having more eyes within 5 degrees</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1328</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Comfort.</title>
        <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale, 1=most negative response to 5=most positive response, was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control. &gt;0=comfortable, &lt;0=uncomfortable</description>
        <time_frame>15-20 minutes</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
          <group group_id="O3">
            <title>Etafilcon A Sphere</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Comfort.</title>
          <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale, 1=most negative response to 5=most positive response, was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control. &gt;0=comfortable, &lt;0=uncomfortable</description>
          <population>Analysis includes participants who completed the study per protocol (n=88)</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1425" spread="0.1034"/>
                    <measurement group_id="O2" value="-0.3464" spread="0.1035"/>
                    <measurement group_id="O3" value="0.2176" spread="0.1028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis was senofilcon A toric was superior to alphafilcon A toric.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4890</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1393</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.1529</ci_lower_limit>
            <ci_upper_limit>0.4890</ci_upper_limit>
            <estimate_desc>Mean difference was senofilcon A toric minus alphafilcon A toric</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Preference</title>
        <description>This outcome measures which lens the subjects preferred to wear.</description>
        <time_frame>end of study</time_frame>
        <population>Analysis includes participants who completed the study per protocol (n=88)</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Toric</title>
          </group>
          <group group_id="O2">
            <title>Alphafilcon A Toric</title>
          </group>
          <group group_id="O3">
            <title>Etafilcon A Sphere</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference</title>
          <description>This outcome measures which lens the subjects preferred to wear.</description>
          <population>Analysis includes participants who completed the study per protocol (n=88)</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Alternative hypothesis was senofilcon A toric was superior to etafilcon A sphere.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A/Alphafilcon A/Etafilcon A</title>
          <description>First Intervention: senofilcon A toric contact lenses Second Intervention: alphafilcon A toric contact lenses Third Intervention: etafilcon A sphere contact lenses</description>
        </group>
        <group group_id="E2">
          <title>Alphafilcon A/Etafilcon A/Senofilcon A</title>
          <description>First Intervention: alphafilcon A toric contact lenses Second Intervention: etafilcon A sphere contact lenses Third Intervention: senofilcon A toric contact lenses</description>
        </group>
        <group group_id="E3">
          <title>Etafilcon A/Senofilcon A/Alphafilcon A</title>
          <description>First Intervention: etafilcon A sphere contact lenses Second Intervention: senofilcon A toric contact lenses Third Intervention: alphafilcon A toric contact lenses</description>
        </group>
        <group group_id="E4">
          <title>Senofilcon A/Etafilcon A/Alphafilcon A</title>
          <description>First Intervention: senofilcon A toric contact lenses Second Intervention: etafilcon A sphere contact lenses Third Intervention: alphafilcon A toric contact lenses</description>
        </group>
        <group group_id="E5">
          <title>Alphafilcon A/Senofilcon A/Etafilcon A</title>
          <description>First intervention: alphafilcon A toric Second intervention: senofilcon A toric Third intervention: etafilcon A sphere</description>
        </group>
        <group group_id="E6">
          <title>Etafilcon A/Alphafilcon A/Senofilcon A</title>
          <description>First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody, OD, FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

